← Back to Search

Tyrosine Kinase Inhibitor

Dasatinib Anhydrous for COVID-19 Infection

Phase 2
Waitlist Available
Led By Ann Mohrbacher, MD
Research Sponsored by University of Southern California
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 month
Awards & highlights

Study Summary

This study is evaluating whether dasatinib may help reduce inflammation caused by COVID-19.

Eligible Conditions
  • COVID-19 Infection

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Proportion of participants requiring invasive mechanical ventilation, requiring tocilizumab or dying
Secondary outcome measures
Absolute lymphocyte count
CRP (C-reactive protein) level
Change of the SOFA (Sequential Organ Failure Assessment)
+4 more

Side effects data

From 2022 Phase 2 trial • 54 Patients • NCT03023046
26%
Febrile neutropenia
17%
Sepsis
9%
Mucositis oral
4%
Upper gastrointestinal hemorrhage
4%
Intracranial hemorrhage
4%
Hypotension
4%
Hypertension
4%
Enterocolitis
2%
Atrial fibrillation
2%
Lower gastrointestinal hemorrhage
2%
Delirium
2%
Oropharyngeal pain
2%
Gastric hemorrhage
2%
Abdominal pain
2%
Diarrhea
2%
Fungemia
2%
Typhlitis
2%
Myocardial infarction
2%
Fibrinogen decreased
2%
Endophthalmitis
2%
Multi-organ failure
2%
Kidney infection
2%
Peripheral motor neuropathy
2%
Hypoxia
2%
Sinus bradycardia
2%
Edema limbs
2%
Small intestinal obstruction
2%
Aspiration
100%
80%
60%
40%
20%
0%
Study treatment Arm
Treatment (Chemotherapy)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm I (dasatinib anhydrous)Experimental Treatment1 Intervention
Patients receive dasatinib anhydrous PO QD for 14 days in the absence of disease progression or unacceptable toxicity.
Group II: Arm II (placebo administration)Placebo Group1 Intervention
Patients receive placebo PO QD for 14 days in the absence of disease progression or unacceptable toxicity.

Find a Location

Who is running the clinical trial?

University of Southern CaliforniaLead Sponsor
906 Previous Clinical Trials
1,596,288 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,665 Previous Clinical Trials
40,925,854 Total Patients Enrolled
18 Trials studying COVID-19 Infection
77,456 Patients Enrolled for COVID-19 Infection
Ann Mohrbacher, MDPrincipal InvestigatorUniversity of Southern California
3 Previous Clinical Trials
49 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Dasatinib for the Treatment of Moderate and Severe COVID-19
2022. "Dasatinib for the Treatment of Moderate and Severe COVID-19". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04830735.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top